Patients who experience substantial weight loss or excellent glycemic control with minimal side effects are more likely to continue long-term therapy
Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Understand Your Medication Before you pick up the pen or vial, know what youre working with
Akkermansia lives in the mucus layer of your intestines
There may be serious allergic reactions
Lin MH, Cheng PC, Hsiao PJ, Chen SC, Hung CH, Kuo CH, et al